Biotechnology industries

Pharmaceutical industry

Oncolytics Biotech Inc. Announces Positive Interim Data from Translational Clinical Trial of REOLYSIN in Metastatic Colorectal Cancer

Preliminary results from a translational clinical trial in the UK have shown promising outcomes for patients with metastatic colorectal cancer treated with REOLYSIN, an oncolytic virus. The study, led by Professor Alan Melcher of the Leeds Institute of Molecular Medicine, involved six patients who received intravenous REOLYSIN prior to surgical

Pharmaceutical industry

Alnylam and Tekmira Collaborate to Develop RNAi Therapeutic for Ebola Virus Infection

Alnylam Pharmaceuticals, a leading developer of RNAi therapeutics, has granted Tekmira Pharmaceuticals a new InterfeRx license to develop an RNAi therapeutic for the treatment of Ebola virus infection. The collaboration is focused on advancing the development of TKM-Ebola, a systemically delivered RNAi therapeutic that utilizes Tekmira's lipid nanoparticle

Pharmaceutical industry

MorphoSys AG and AbD Serotec Secure Exclusive License to Research Antibody from The Institute of Cancer Research

MorphoSys AG, a leading biotechnology company, has announced that its research and diagnostic antibodies unit, AbD Serotec, has signed a license agreement with The Institute of Cancer Research (ICR), London, to commercialize a widely used BrdU antibody clone for research applications. The agreement grants AbD Serotec worldwide exclusive rights to

Pharmaceutical industry

Myriad Genetics and Abbott Laboratories Collaborate on Clinical Study of Metastatic Breast Cancer Treatment

Myriad Genetics, a leading molecular diagnostic company, has partnered with Abbott Laboratories to conduct a Phase III multi-centre, multi-national clinical study on a novel drug candidate for metastatic breast cancer. This collaboration builds upon a previous agreement for a Phase II study with the same study drug. Under the agreement,

Pharmaceutical industry

Oncolytics Biotech Inc Announces Promising Interim Data from UK Translational Clinical Trial of Reolysin in Colorectal Cancer

Oncolytics Biotech Inc has made significant progress in the development of its oncolytic virus, Reolysin, designed to target and destroy cancer cells. A recent presentation at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation in Pamplona, Spain, shared exciting interim data from a UK translational clinical trial, REO 013.

Pharmaceutical industry

Molecular Insight Pharmaceuticals Presents Positive Data from Phase 1 Clinical Studies for Trofex and Prostate Cancer Imaging

Molecular Insight Pharmaceuticals has presented positive data from Phase 1 clinical studies comparing its lead molecular imaging candidate, Trofex, with ProstaScint for the diagnosis and monitoring of metastatic prostate cancer. The studies demonstrated that Trofex rapidly detected prostate cancer localized in the prostate bed, soft tissues, and bone within four

Pharmaceutical industry

Brentuximab Vedotin Demonstrates Significant Efficacy in Relapsed or Refractory Anaplastic Large Cell Lymphoma

Seattle Genetics and Millennium announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients. The trial achieved an objective response rate of 86%, with 80% of patients in the trial experiencing some form of response.

Pharmaceutical industry

Sanofi-Aventis Launches $18.5 Billion Hostile Takeover Bid for Genzyme Corp.

Sanofi-Aventis, a French pharmaceutical company, has launched a hostile takeover bid for Genzyme Corp., a US-based biotech company, valuing the deal at $18.5 billion. The offer, which is unchanged from a friendly bid made in July, values Genzyme shares at $69 per share, representing a 38% premium over their

Pharmaceutical industry

BioCentury Welcomes Top Life Science CEOs from China to the San Francisco Bay Area

BioCentury Publications, Inc., a leading global provider of biotech news and analysis, recently welcomed the CEOs of the top three life science companies from the Greater China SEED Business Plan Competition to the San Francisco Bay Area. The CEOs received the "BioCentury SEED Winners Tour" award and participated

Pharmaceutical industry

Sanofi-Aventis Considers Boosting Bid for Genzyme

Sanofi-Aventis is reportedly contemplating increasing its USD18.5 billion all-cash takeover offer for Genzyme to USD69 per share, with a potential boost of USD1 to USD2 per share expected in the coming week. This decision comes after Genzyme rejected Sanofi's initial offer, citing undervaluation of the company. The

Pharmaceutical industry

Health Care Stocks Mixed to Lower in Late Trading

Health care stocks are experiencing a mixed bag as the day comes to a close, with some notable updates in the sector. Sanofi-Aventis is considering raising its bid for Genzyme Corp., while Allergan Inc. sees an increase in its shares after the FDA approves its eye inflation drug Ozurdex. Meanwhile,

Pharmaceutical industry

US Biotechnology Industry Booms with $90 Billion in Revenue

The US biotechnology industry, comprising about 1,500 companies, has a combined annual revenue of more than $90 billion. The sector is driven by demand for new medical treatments, the need to produce more food for a growing population, and scientists' pursuit of solutions for complex scientific and medical